MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    The relationship between cognitive aspects (education status, executive function and verbal fluency) and motor aspects (balance and gait) in patients with Parkinson’s disease

    C.O. Souza, M.C. Voos, H.F. Chien, D.V. Francato, A.F. Barbosa, J.M. Greve, E.T. Fonoff, E.R. Barbosa (Sao Paulo, Brazil)

    Objective: The aim of this study was to verify if there would be correlations between cognitive variables (educational status, executive function, verbal fluency) and motor…
  • 2016 International Congress

    Dopaminergic drug management in Parkinson’s disease: Gait and language function show correlation during treatment

    H. Murakami, A. Futamura, T. Kuroda, S. Ishigaki, M. Kezuka, K. Ono, M. Kawamura (Tokyo, Japan)

    Objective: We examined the effects of dopaminergic medication adjustment on cognitive function in Parkinson's disease (PD) patients without apparent dementia (Mini-Mental State Examination score of…
  • 2016 International Congress

    Optic nerve integration as a visuospatial cognitive predictor in Parkinson’s disease

    J.J. Lee, Y. Lee, S.J. Chung, Y.H. Sohn, P.H. Lee (Seoul, Korea)

    Objective: To explore the microstructural integrity of the optic nerve and its role as a cognitive predictor in patients with de novo Parkinson's disease (PD)…
  • 2016 International Congress

    Cerebrospinal fluid biomarkers in Parkinson’s disease and associated cognitive impairment

    M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

    Objective: Our aim is to assess CSF levels of amyloid-β1-42 (Aβ1-42), T-Tau, threonine-181 phosphorilated tau (P-Tau) and α-synuclein (α-syn) as well as different ratios of…
  • 2016 International Congress

    Investigation of driving ability to drive safely in patients with Parkinson’s disease by interview

    R. Ando, C. Yamazaki, H. Iwaki, H. Yabe, N. Nishikawa, M. Nagai, K. Nakashima, M. Nomoto, Safe Driving Study Group of Japan (Tohon, Japan)

    Objective: We investigated the vehicle driving situation, clinical signs and symptoms of PD patients to obtain the information for safe driving. Background: PD neurologists are…
  • 2016 International Congress

    Defective visual perception in patients with Parkinson’s disease: The impairment of preattentive visual processing in the normal intellectual patients

    Y. Higashi, T. Tabuchi, M. Tabata, E. Mori (Himeji, Japan)

    Objective: In the previous conference, we reported that the impairment of preattentive visual processing could be detected even among subjects considered to have normal cognitive…
  • 2016 International Congress

    Speech prosody impairment predicts cognitive decline in Parkinson’s disease

    I. Rektorova, J. Mekyska, E. Janousova, M. Kostalova, M. Mrackova, I. Eliasova, D. Berankova, R. Marecek (Brno, Czech Republic)

    Objective: We assessed whether baseline speech prosodic parameters, alone or in combination with other predominantly non-dopaminergic symptoms may predict global cognitive decline as measured by…
  • 2016 International Congress

    Cytokines in CSF and plasma as potential biomarkers for PD cognitive impairment

    M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

    Objective: To assess CSF and plasmatic levels of cytokines as potential biomarkers of PD and PD mild cognitive impairment (PD-MCI). Background: Neuroinflammation may play a…
  • 2016 International Congress

    Association between urine protein/creatinine ratio and cognitive dysfunction in Parkinson’s disease

    Y.S. Oh, J.S. Kim, K.S. Lee (Seoul, Korea)

    Objective: We investigated the relationship between proteinuria and cognitive dysfunction in patients with Parkinson's disease. Background: Impaired renal function and proteinuria have been associated with…
  • 2016 International Congress

    Piperine potentiates neuroprotective effect of curcumin in MPTP model of Parkinson’s disease in rats: Impact on neurochemical modulation

    S. Singh, P. Kumar (Moga, India)

    Objective: (1) Curcumin is well tolerated phenolic compound used for CNS disorder but problem is its low oral bioavailability and (2) Piperine is combined to…
  • « Previous Page
  • 1
  • …
  • 1481
  • 1482
  • 1483
  • 1484
  • 1485
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25179 (not found)
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley